PIER MARIA FORNASARI
2022-04-08

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

CD19 CAR T-cell therapy is effective at achieving durable remission for relapsed/refractory ALL across cytogenetic risk groups. CD19 CAR T-cell treatment results for patients with high-risk cytogenetics including Ph+, Ph-like, and KMT2A-rearranged ALL are encouraging. Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-04-08

COVID-19: brain impact of SARS-CoV-2 on the nervous system

Emerging studies have increasingly recognized Covid-19 as an inflammatory disease. Brain shrinkage, brain-blood barrier disruptions and neurodegeneration seem to emerge as an inflammatory consequence of acute infection that for some progresses into Long Covid. Cognitive impairments are consistently reported as one of the most persistent and some of the more impairing symptoms of Long Covid.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-04-07

ALY101 molecule holds promise in potential therapies for cancer and rare diseases

Researchers at the University of California, Irvine and the Italian Institute of Technology have developed a new molecule, ALY101, that shows promising anti-cancer activity against a wide range of tumor cell types and in mouse models of a common type of melanoma. The findings, “Structure-based Design of CDC42 Effector Interaction Inhibitors for the Treatment of

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2022-04-07

Penn Medicine Study: Pulse Oximeters Did Not Change Outcomes for Patients in COVID-19 Monitoring Program

Already monitored for worsening symptoms via automated text messages, patients with pulse oximeters in the COVID Watch program had similar recovery to those without them. Using a pulse oximeter to measure oxygen levels is no better than just regularly asking patients with COVID-19 if they are short of breath, according to new research at the

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-04-07

Covid-19 increases the risk of blood clots up to six months after infection

The risk of pulmonary embolism and venous thrombosis is multiplied by a corona infection. According to a new study of all those who tested positive in Sweden, this applies six months after the diagnosis. According to a study, people infected with SARS-CoV-2 have an increased risk of developing severe blood clots for up to six months after infection . According

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-04-07

A Mount Sinai-led team developed a reproducible and scalable method to advance maturation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)

A study reporting this new protocol was published in the April 7 print edition of the journal Cell Stem Cell. A Mount Sinai-led team has developed a reproducible and scalable method to advance maturation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)—cells that support heart muscle contraction, generated in the lab from human stem cell lines—which researchers

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2022-04-06

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

BACKGROUND Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)–based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter. The efficacy and safety of the therapy were previously evaluated in men with severe hemophilia A in a phase 1–2 dose-escalation study. METHODS Was conducted an open-label, single-group, multicenter, phase 3

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-04-06

CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori to better fight cancer

Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at Uppsala University have now developed armed CAR-T cells that reinforce the immune defense against cancer and that could increase the possibilities to successfully treat solid tumors. The study has been published in the journal Nature Biomedical Engineering. The use of immunotherapy to treat cancer

Read More

No Comments InCAR-T